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ABSTRACT: 31 
Background: In Peru, a treatment approach for XDR-TB that incorporated WHO group 32 
5 drugs and a patient-centered care, has achieved 65% success. To expand this 33 
approach for pre-XDR-TB, we have evaluated this population separately.  34 
Objective: To assess programmatic management of pre-XDR-TB. 35 
Method: Retrospective study using official registry from 2011 to 2014. Cases were 36 
separately evaluated according to resistance to fluoroquinolones (pre-XDR-F) or 2
nd
 37 
line injectable drugs (SLIs) (pre-XDR-I). 38 
Results: From 610 pre-XDR-TB patients, 120 (20%) had pre-XDR-F and 490 (80%) had 39 
pre-XDR-I. The pre-XDR-F cases were older (34 vs 28 years, p<0,001) and a higher 40 
proportion had previously received two or more regimens (70% vs 38%, p<0,001). In 41 
the 452 cases who started treatment in 2011-2013, treatment success was 43.3%, 42 
26.5% were lost to follow-up, 12.1% died and 13.7% failed treatment. Success was 43 
higher in pre-XDR-I (48.5%) than pre-XDR-F (21.4%). History of previous treatment (OR 44 
2.23, CI 1.52-3.38) and pre-XDR-F (OR 2.39, CI 1.18 - 4.83) were associated with 45 
unsuccessful outcome. 46 
Conclusion: Programmatic management of pre-XDR-TB has not been successful, 47 
especially in pre-XDR-F, with lower rates of success than have been achieved in the 48 
same setting for XDR-TB. The strategy used for XDR-TB should be expanded to pre-49 
XDR-TB in Peru.   50 
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INTRODUCTION  51 
Drug-resistant tuberculosis (TB) poses a challenge for TB elimination, with 660,000 52 
estimated new cases resistant to rifampicin (RR-TB), of which 490,000 had multidrug-53 
resistant TB (MDR-TB) with resistance to at least isoniazid (H) and rifampicin (R) in 54 
2016 worldwide. 
1
 Among MDR-TB cases, 6.2% fulfil the criteria for XDR-TB with 55 
additional resistance to a fluoroquinolone and a second line injectable drug (SLI) 56 
[kanamycin (Km), capreomycin (Cm) or amikacin (Am)]. 
1
 Pre-XDR-TB is defined as 57 
MDR-TB with resistance to either a fluoroquinolone (pre-XDR-F) or a SLI (pre-XDR-I), 58 
but not both. 
2
 The burden of pre-XDR-TB is considerable and represents a threat to 59 
MDR-TB control; the proportion of MDR-TB with resistance to any fluoroquinolone was 60 
estimated at 21% worldwide in 2015, with an overall 51% with resistance to a 61 
fluoroquinolone or a SLI. 
3
 62 
In 2015, Peru reported 1,366 cases of MDR-TB and 104 cases of XDR-TB. 
4
 Since 2011, 63 
Peru has provided individualized treatment for MDR-TB based on drug susceptibility 64 
testing (DST) of first and second-line agents, as per WHO recommendations, with at 65 
least 4 effective drugs delivered through the primary health care system 
5
. MDR-TB 66 
treatment success rate in 2013 was 55%, with 29% of patients lost to follow-up, data 67 
that included pre-XDR TB. During the same period, a more aggressive and multi-68 
faceted approach to the treatment of XDR-TB entailed: i) the additional use of drugs 69 
from Group 5 of the former WHO classification and thioridazine (not used for non-XDR 70 
MDR-TB), ii) a comprehensive care package starting in hospital, with follow-up at home 71 
and ending in primary care, iii) direct observation of treatment, iv) additional social 72 
support, v) improved monthly food baskets and vi) infection control measures in the 73 
home. 
4
 With this package of interventions, the treatment success for XDR-TB rose 74 
from 30% in 2011 to 66% in 2013 (higher than for programmatic management of MDR-75 
TB), while loss to follow-up decreased from 27% to 2%. 
6
 76 
Resistance to fluoroquinolones and SLIs reduces the success rate for MDR-TB therapy, 77 
and though there are a growing number of studies on XDR-TB treatment 
7-9
 there is a 78 
scarcity of data on the much more common pre-XDR-TB. 
2, 10
 The National Tuberculosis 79 
Programme (NTP) in Peru suspected that the low success rate in MDR-TB might be due 80 
to poor treatment outcomes amongst pre-XDR-TB cases, which are normally included 81 
Page 3 of 22
For Review Only
4 
 
in the MDR-TB cohort. The objective of this study was to assess retrospectively the 82 
programmatic management of pre-XDR-TB cases who started treatment between 2011 83 
and 2014, evaluate time between diagnosis and treatment initiation, drugs used, 84 
culture conversion and treatment outcome among those who started treatment in 85 
2011-2013, disaggregated into cases with pre-XDR-F and pre-XDR-I.  86 
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METHODS 87 
The operational study to compare retrospective cohorts of pre-XDR-TB cases.  88 
Context: Since 2013, the NTP has required DST to R and H for all diagnosed TB cases in 89 
the country using direct rapid assays validated in the country, either nitrate reductase 90 
(Griess) assay 
11
, direct microscopic-observation drug-susceptibility (MODS) assay 
12, 13
 91 
or molecular line probe assay (LPA). 
14
. On detection of H or R resistance, indirect 92 
culture-based DST for first and second line drugs using Middlebrook 7H10 agar plates 93 
proportion (APP) assay is performed at the National Mycobacterial Reference 94 
Laboratory, with annual external quality evaluation by the Supranational Laboratory of 95 
WHO. Among fluoroquinolones, ciprofloxacin was tested, and for SLI kanamycin (Km) 96 
and capreomycin (Cm). Before and even after the 2013 national standard was issued, 97 
DST continued to be performed using the indirect proportion method in APP or 98 
Lowenstein Jensen (LJ) medium. Due to delays in results of indirect DST, many patients 99 
started standardized treatment with second-line drugs after having failed first-line 100 
treatment, or because they were contacts of MDR-TB, before obtaining indirect DST 101 
results.  102 
Evaluation Committees on Retreatment approved regimens for MDR-TB cases, and 103 
treatment was administered on an outpatient basis at the first level of care, at the 104 
clinic nearest to the patient's home. MDR-TB regimens based on rapid H and R assays 105 
were later adjusted to individualized regimens when the APP became available, 106 
according to Peruvian guidelines 
15, 16
.  In some cases, the regimen was maintained if 107 
the clinical course was favorable. The best available drugs were selected, based on the 108 
previous WHO classification into five groups, including at least four effective drugs 
5
. In 109 
cases of pre-XDR-TB, a fluoroquinolone or an SLI was included; in case of 110 
fluoroquinolone resistance, moxifloxacin (Mfx) was added, and in case of SLI 111 
resistance, Cm or amikacin (Am) were added, in both cases these drugs were not 112 
counted as one of the four required effective drugs. Ethionamide (Eto), cycloserine (Cs) 113 
and ethambutol (E) were added if the strain was still susceptible to these drugs, usually 114 
maintaining pyrazinamide (Z). In cases with resistance to Eto, the drugs E, Z and/or 115 
para-aminosalicylic acid (PAS) were always added with the goal to get four effective 116 
drugs.  117 
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The elevated cost of group 5 drugs plus hospitalization, insertion of a central line for 118 
carbapenems, and DOT in the household had a high cost for the government; these 119 
drugs were therefore limited to XDR-TB cases. For pre-XDR-TB a supposedly adequate 120 
individualized regimen could be designed based on either a fluoroquinolone or a SLI, 121 
plus Eto, E, Z, Amx-Clv, Cs and PAS in line with WHO guidelines of 2011. 
5
 Confirmed 122 
cases of XDR-TB were treated also with linezolid (Lzd), carbapenems plus amoxicillin 123 
clavulanate (Amx-Clv), as well as thioridazine 
4
. Bacteriological conversion was 124 
monitored by monthly sputum cultures. 
15
 125 
 126 
Study population: Pulmonary pre-XDR-TB patients who started treatment from 127 
January 2011 to December 2014 were included. Patients were classified in two cohorts 128 
based on fluoroquinolone (ciprofloxacin) resistance (pre-XDR-F TB), or resistance to 129 
one or both SLIs (Km, Cm) (pre-XDR-I TB), as assessed by APP. Patients of all ages and 130 
from all over the country were included. For treatment outcome, the subgroup of 131 
patients who started treatment in 2011-2013 was assessed. Treatment outcomes 132 
were: cured, treatment completed, failure, lost to follow-up, deceased, and not 133 
evaluated, in accordance with WHO Guidelines. 
17
 Two authors examined the clinical 134 
records of all patients to determine treatment outcome. For evaluating monthly 135 
culture results and treatment outcome, the group of pre-XDR-I was subdivided in 136 
three: pre-XDR-Km, pre-XDR-Cm and pre-XDR-Km-Cm. 137 
Data collection: The National Resistant Tuberculosis Registry was used, which is 138 
updated daily with quarterly reports of each resistant TB case in the country. The 139 
result of the DST was checked with the computerized NETLAB database. 
18
 140 
Demographic variables, treatment history, comorbidities, monthly culture results, DST 141 
results, treatment regimens, and outcomes were evaluated in accordance with WHO 142 
guidelines. The outcomes were re-categorized in successful (cure and completed 143 
treatment) and unsuccessful (failure, death, lost to follow-up and not evaluated). 144 
Statistical analysis: The database was analyzed using STATA version 14.2 (Stata corp, 145 
Texas, USA). Clinical and epidemiological characteristics were compared between pre-146 
XDR-F and pre-XDR-I patients. A Chi-squared test (X
2
) was used to assess the 147 
association between categorical variables, while a Wilcoxon test was used for 148 
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continuous variables. In the subgroup of patients registered in 2011-2013, treatment 149 
outcome was compared between pre-XDR-F and pre-XDR-I cases and injectable 150 
subgroups. A p-value <0.05 was considered to define a significant difference. 151 
Multivariate analysis was performed to identify factors significantly associated with 152 
unsuccessful treatment outcome. 153 
Ethical considerations: The protocol was approved by the Ethics Committees at the 154 
Hospital Nacional Hipólito Unanue, and from The Union.  155 
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RESULTS 156 
A total of 610 pre-XDR-TB patients who started treatment in 2011-2014 were included: 157 
120 (19.7%) with pre-XDR-F and 490 (80.3%) with pre-XDR-I. Among pre-XDR-I, 213 158 
(43.5%) were resistant to Km only, 102 (20.8%) were resistant to Cm only, and 175 159 
(35.7%) were resistant to both injectable drugs.   160 
Male gender was more common in both cohorts, median age was 29 years old. 161 
Diabetes mellitus was recorded for 8% of patients and HIV in 4%. Among pre-XDR-TB 162 
patients, 67% had undergone two or more previous courses of TB treatment. Pre-XDR-163 
F patients were significantly older (median 34 vs 28 years, p<0.001), more commonly 164 
reported both diabetes and previous treatment episodes: 70% had received two or 165 
more prior courses of treatment vs. 38% of pre-XDR-I patients (p<0.001) and most of 166 
them received their treatment after previous loss to follow-up (Table 1).  167 
Treatment for drug-resistant TB was started in 29% of patients pending bacteriological 168 
confirmation with an indirect DST. Treatment was started in 39% of patients less than 169 
two weeks after diagnosis, and 32% after more than 3 weeks, with no significant 170 
differences between the groups (Table 2). 171 
The drugs from the individualized regimens that were used in more than 50% of the 172 
patients, were grouped based on the resistance pattern: i) for pre-XDR-F: Cm, Z, Mfx, 173 
Cs, Eto and Amx-Clv, ii) for pre-XDR-I Km-resistant: Z, Cm, Lfx, PAS, Cs and Eto, iii) for 174 
pre-XDR-I Cm-resistant:  Z, Lfx, PAS, Cs, Eto and Amx-Clv and iv) for pre-XDR-I Km+Cm-175 
resistant: Z, Lfx, PAS, Cs, Eto and Amx-Clv. Drugs from previous Group 5 and 176 
thioridazine were very rarely used (Table 3). 177 
Of the 610 patients, 342 (56%) had achieved bacteriological conversion by the sixth 178 
month; this was higher in the pre-XDR-I group (60.6%) than in pre-XDR-F group 179 
(42.5%), p<0.001. The proportion with positive culture by month of treatment was 180 
higher in the pre-XDR-F group, followed by the pre-XDR Km+Cm (Figure 1). The 181 
number not assessed for conversion (because of death, loss to follow-up or missing 182 
information) were in total 157 (26%): 41 (34%) pre-XDR-F, 53 (25%) pre-XDR-Km, 25 183 
(25%) pre-XDR-Cm and 38 (22%) pre-XDR-Km+Cm. 184 
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Among the 452 patients who started treatment in 2011-2013, 43.4% were successfully 185 
treated, 26.5% were lost to follow-up, 13.7% had treatment failure, 12.2% were 186 
deceased, and in 4.2% treatment outcome was not evaluated. A successful treatment 187 
outcome was significantly less likely in patients with pre-XDR-F (21.4%) vs. pre-XDR-I 188 
(48.5%), p<0.001. Among pre-XDR-I patients, the lowest success rate was seen in 189 
patients with resistance to both Km and Cm (Table 4). Among patients with lost to 190 
follow result, 48% occurred during first to six month, 34% at seven to 12 month, and 191 
18% after 12 months. Treatment failure and death rates were lower in pre-XDR-I with 192 
Cm resistance. The highest proportion of death (22.6%) was in the pre-XDR-F type. In a 193 
multivariate model, the only variables independently associated with unsuccessful 194 
outcome were a history of previous treatment and resistance to fluoroquinolones (pre-195 
XDR-F), OR 2.23 (1.52 - 3.38), p<0.001 and OR 2.39 (1.18 - 4.83), p<0.015, respectively   196 
(Table 5). 197 
  198 
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DISCUSSION 199 
The study is one of few published on programmatic management of pre-XDR-TB and 200 
the first nationwide study in Peru. The overall success rate in pre-XDR was low, even 201 
surprisingly lower than XDR-TB but this reflects the intensive attentio
2
n paid to 202 
treating XDR-TB patients in Peru, with particularly strengthened treatment regimens, 203 
patient-centralized DOT, and social support. 
4
 The study confirmed significantly lower 204 
treatment success in pre-XDR-TB with resistance to fluoroquinolones than to SLI, as 205 
also found in previous reports. 
2, 10
 206 
Even though pre-XDR-TB patients were diagnosed quickly and treated in line with WHO 207 
recommendations, 
5
 the majority of cases had unfavorable outcomes. The most 208 
frequent unfavorable outcome was lost to follow up with 26.4%, which were more 209 
frequent in the first six months, and probably due to long and weak treatment 210 
regimens, clinic-centered DOT, adverse reactions,  inadequate social support, and 211 
limitations of the health system to follow up timely patients who take their treatment 212 
irregularly. The high death rate was likely due in the early years to a delay in DST 213 
results for second-line drugs (with conventional method) and late treatment initiation, 214 
although it subsequently remained high even though rapid DST coverage was 215 
increased. Comorbidities or coinfections may have contributed to the increased 216 
mortality as well. The death rate was higher in pre-XDR-F than pre-XDR-I, possibly 217 
because these patients were older and had received more previous treatments. 218 
Acquired resistance may explain the high failure rate as patient already with pre-XDR 219 
were started on standardized MDR-TB treatment because DST results came late. 220 
Fluoroquinolone resistance was only tested to ciprofloxacin. Probably a considerable 221 
proportion of strains with resistance to ciprofloxacin maintained susceptibility to 222 
levofloxacin or moxifloxacin with which they were treated, but still ciprofloxacin 223 
resistance was associated with poor outcome in a multivariable model. There was no 224 
DST for Am so the use of this injectable may not have been optimal.   225 
Our study is unusual in finding higher success rate in XDR-TB than pre-XDR-TB; lower 226 
treatment success rate in pre-XDR-F than pre-XDR-I has also been found in other 227 
studies. Data from 6724 MDR-TB patients with personalized treatment in 26 sites 228 
worldwide showed a 64% success rate in cases with no resistance to injectable or 229 
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fluoroquinolones, 56% in pre-XDR-I, 48% in pre-XDR-F and 40% in XDR. Failure/relapse 230 
rate increased with increasing resistance (from 4% in MDR-TB to 22% in XDR-TB), as 231 
did deaths (from 8 to 15%), but not the proportion lost to follow-up (18-16-12-16%, 232 
respectively) 
10
.
 
In 1407 MDR-TB patients from Korea, similar data were observed, with 233 
a 47% success rate in cases with no fluoroquinolone and injectable resistance, the 234 
same success rate (47%) in patients with pre-XDR-I, but lower in pre-XDR-F (36%) and 235 
in XDR (29%). Failure and death rates increased with increased resistance, while 236 
patients lost to follow-up decreased with increasing resistance.
 2
  237 
A strength was that the study was nation-wide, with DST done centralized in an 238 
externally quality assured reference laboratory. One limitation was that 239 
fluoroquinolone susceptibility was only tested for ciprofloxacin, while treatment 240 
included levofloxacin or moxifloxacin. Another limitation was incomplete culture 241 
conversion data because data were missing or many patients lost or died.  Instead, the 242 
proportion of all cases with positive culture by month was shown for each subgroup, 243 
but such grouped data must be interpreted with caution. Recording of adverse drug 244 
reactions was incomplete at central level, so that the relationship with loss to follow-245 
up could not be assessed. 246 
The recommendations arising from our findings are that: i) pre-XDR-TB cases should be 247 
handled similarly to XDR TB cases, incorporating new effective drugs (current WHO 248 
Groups C & D) with special care for patients resistant to fluoroquinolones, ii) all MDR-249 
TB patients (and not just XDR-TB patients) need patient-centered strategies to prevent 250 
and reduce loss to follow-up, with strictly supervised home treatment (intensive 251 
phase) and then as outpatients at the health facility (continuation phase), iii) rapid DST 252 
for fluoroquinolone and SLI should be implemented in MDR-TB high burden countries, 253 
iv) surveillance for adverse events should be improved, and v) patient cohort outcomes 254 
should be evaluated separately for MDR-TB, pre-XDR-F TB, pre-XDR-I TB and XDR-TB.   255 
Our results suggest that the current definition of pre-XDR-TB as a distinct entity may 256 
not be a very useful concept since it consists of two very different groups with 257 
different treatment success rates. As of January 2016, pre-XDR-TB patients have been 258 
managed under the same conditions as XDR-TB patients in Peru and in line with other 259 
reports 
19
 and WHO guidelines from 2016. 
20
  260 
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In conclusion, previous programmatic management of pre-XDR-TB, treated as other 261 
MDR-TB patients, had too low success rate, especially in cases of pre-XDR-F. Rapid 262 
drug susceptibility testing for fluoroquinolones and SLIs, patient-centered strategies 263 
and regimens including new drugs are needed. 264 
  265 
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Table 1. General characteristics of the study population of pre-XDR-TB patients 338 
who started treatment, Peru:  2011-2014 339 
 340 
Characteristics  Pre-XDR-F 
(N=120) 
Pre-XDR-I 
(N=490) 
Total 
(N=610) 
p-value 
n (%) n (%) n (%)   
Male 90 (75) 325 (63) 415 (68) 0.07 
Age groups     
0 - 14 years 1 (1) 5 (1) 6 (1)  
15 - 34 years 62 (52) 332 (68) 394 (65)  
35 - 54 years 42 (35) 123 (25) 165 (27)  
55 years or more 15 (13) 30 (6) 45 (7)  
Age - median (IQR) 34 (27 - 45) 28 (22 - 38) 29 (22 - 
40) 
<0.001 
HIV-positive 5 (4) 18 (4) 23 (4) 0.71 
Diabetes mellitus 17 (14) 29 (6) 46 (8) 0.002 
Place of origin     
Lima and Callao 86 (72) 393 (80) 479 (79) 0.041 
Number of previous treatments     
No previous treatments 20 (17) 183 (37) 203 (33) <0.001 
1 previous treatment 16 (13) 121 (25) 137 (22)  
2 or more previous treatments 84 (70)  186 (38) 270 (44)  
Treatment history     
 New 20 (17) 183 (37) 203 (33) <0.001 
 Relapse 12 (10) 53 (11) 65 (11)  
Treatment after loss to follow-up 65 (54) 169 (34) 234 (38)  
Treatment after failure 23 (19) 85 (17) 108 (18)  
Year of treatment initiation     
2011 33 (28) 133 (27) 166 (27) 0.136 
2012 19 (16) 125 (26) 144 (24)  
2013 32 (27) 111 (23) 143 (23)  
2014 36 (30) 121 (25) 157 (26)   
 341 
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Table 2. Days from diagnosis to treatment initiation for pre-XDR-TB, Peru: 2011-343 
2014 344 
 345 
Treatment initiation Pre-XDR-F Pre-XDR-I Total p-
value 
(N=120) (N=490) (N=610)  
Before diagnosis, n (%) 33 (28) 143 (29) 176 (29) 0.80 
After diagnosis, n (%) 87 (72) 347 (71) 434 (71)  
Before diagnosis, median (IQR) -30 (-66, -7)  -22 (-58, -8)  -225 (-61, -8)  0.79 
After diagnosis, median (IQR) 14.5  (7, 28)  14 (6, 23)  14 (6, 24)  0.23 
After diagnosis:        
  Less than 2 weeks, n (%) 50 (42) 187 (38) 237 (39) 0.54 
  3-4 weeks, n (%) 20 (17) 101 (21) 121 (20) 0.40 
  Over 4 weeks, n (%) 17 (14) 59 (12) 76 (12) 0.63 
 346 
IQR: Interquartile range 347 
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Table 3. Drugs used according to resistance pattern in pre-XDR-TB patients, 349 
Peru: 2011-2014 350 
Resistance 
pattern 
Pre-XDR-F Pre-XDR-Km Pre-XDR-Cm Pre -XDR-Km+Cm Total 
n  (%)  n  (%)  n  (%)  n  (%)  n (%)  
Total 120  213  102  175  610  
E 43 (36) 89 (42) 34 (3) 52 (30) 218 (36) 
Z 77 (64) 148 (70) 70 (69) 137 (78) 432 (71) 
S 3 (3) 8 (4) 2 (2) 16 (9) 29 (5) 
Km 22 (18) 18 (9) 34 (33) 56 (32) 130 (2) 
Cm 57 (48) 164 (77) 5 (5) 71 (41) 297 (49) 
Am 22 (18) 18 (9) 34 (33) 56 (32) 130 (21) 
Cfz 0 (0) 3 (1) 0 (0) 1 (1) 4 (1) 
Lfx 33 (28) 140 (66) 81 (80) 89 (51) 343 (56) 
Mfx 77 (64) 66 (31) 17 (17) 81 (46) 241 (40) 
PAS 61 (51) 118 (55) 57 (56) 105 (60) 341 (56) 
Cs 105 (88) 203 (95) 100 (98) 168 (96) 576 (94) 
Thz 4 (3) 3 (1) 0 (0) 6 (3) 13 (2) 
Eto 76 (63) 127 (60) 83 (81) 98 (56) 384 (63) 
Lzd 4 (3) 4 (1) 0 (0) 6 (3) 14 (2) 
Amx-Clv 61 (51) 90 (42) 36 (35) 100 (57) 287 (47) 
Imp 3 (3) 0 (0) 0 (0) 3 (2) 6 (1) 
 351 
 352 
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Table 4. Clinical outcomes for pre-XDR-TB cases according to baseline 354 
resistance pattern, Peru: 2011-2013  355 
 356 
Treatment 
outcomes 
Pre-XDR-
F 
Pre-XDR-
Km 
Pre-XDR-
Cm 
Pre-XDR 
Km-Cm 
Total 
P Value 
(n=83 (n=155) (n=73) (n=141) (n=452) 
Success 18 (21.7) 81 (52.3) 37 (50.7) 60 (42.6) 196 (43.4) <0.001 
Lost to follow-up 25 (30.1) 35 (22.6) 28 (38.4) 32 (22.7) 120 (26.5) 0.043 
Failure  15 (18.1) 18 (11.6) 3 (4.1) 26 (18.4) 62 (13.7) 0.018 
Death 19 (22.9) 16 (10.3) 2 (2.7) 18 (12.8) 55 (12.2) 0.0016 
Not evaluated 6 (7.2) 5 (3.2) 3 (4.1) 5 (3.5) 19 (4.2) 0.276 
Values are n (%) 357 
Statistical analyses were performed using chi-squared test 358 
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Table 5. Factors associated with unsuccessful treatment outcome in pre-XDR-TB 360 
patients, Peru: 2011-2013 361 
Variables Univariate analysis Multivariate analysis 
  OR CI p-value OR CI p-value 
Age 1.02 1.003 - 1.03 <0.016 1.01 0.99 -1.03 0.20 
Male sex 1.42 0.97-2.1 <0.071 1.32 0.89 - 1.97 0.17 
HIV+ 0.87 0.32-2.29 0.774 
   
Diabetes 1.64 0.81-3.34 0.17 1.29 0.58 - 2.88 0.53 
Previously treated 2.54 1.73-3.74 <0.001 2.23 1.52 - 3.38 <0.001 
Pre-XDR-F 3.07 1.78-5.3 <0.001 2.39 1.18 - 4.83 <0.015 
Pre-XDR-I (Km-resistant) 0.61 0.41-0.89 <0.012 0.94 0.57 - 1.58 0.84 
Pre-XDR-I (Cm-resistant) 0.91 0.64-1.31 0.613 
   
Pre-XDR (Km+Cm-
resistant) 
1.06 0.72-1.57 0.77 
   
Origin: Lima 0.97 0.63-1.5 0.91 
   
 362 
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Figure 1. Proportion of all pre-XDR patients with positive culture according to 364 
month of treatment and pre-XDR types 365 
 366 
 367 
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Basal Mes 1 Mes 2 Mes 3 Mes 4 Mes 5 Mes 6 Mes 7 Mes 8 Mes 9 Mes 10 Mes 11 Mes 12 Mes 13 Mes 14 Mes 15 Mes 16 Mes 17 Mes 18 Mes 19 Mes 20
pre-XDR-F Positivo 81 27 23 21 18 16 20 18 13 14 10 14 10 9 5 7 7 3 2 2 3
Negativo 23 35 32 31 27 35 27 21 20 27 24 21 23 20 18 18 14 19 13 10 7
No evaluado 16 58 65 68 75 69 73 81 87 79 86 85 87 91 97 95 99 98 105 108 110
pre-XDR-Km Positivo 131 44 28 20 23 19 14 14 16 13 11 11 11 11 9 6 6 6 4 4 3
Negativo 54 85 81 90 74 86 86 67 78 77 64 64 60 55 60 53 61 53 43 34 30
No evaluado 28 84 104 103 116 108 113 132 119 123 138 138 142 147 144 154 146 154 166 175 180
pre-XDR-Cm Positivo 71 28 11 9 6 5 6 6 4 3 4 3 4 3 3 1 3 3 3 1 0
Negativo 21 38 49 46 42 39 35 33 37 34 35 19 28 30 28 28 22 20 20 16 13
No evaluado 10 36 42 47 54 58 61 63 61 65 63 80 70 69 71 73 77 79 79 85 89
pre-XDR-Km-Cm Positivo 121 41 19 24 24 28 24 25 22 21 20 15 15 9 10 11 8 6 4 4 5
Negativo 38 56 75 71 69 58 55 49 54 54 50 51 47 50 41 46 37 30 33 27 33
No evaluado 16 78 81 80 82 89 96 101 99 100 105 109 113 116 124 118 130 139 138 144 148
Basal Month 1 Month 2 Month 3 Month 4 Month 5 Month 6 Month 7 Month 8 Month 9 Month 10Month 11Month 12Month 13Month 14Month 15Month 16Month 17Month 18Month 19Mes 20
pre-XDR-F 78% 44% 42% 40% 40% 31% 43% 46% 39% 34% 29% 40% 30% 31% 22% 28% 33% 14% 13% 17%
pre-XDR-Km 71% 34% 26% 18% 24% 18% 14% 17% 17% 14% 15% 15% 15% 17% 13% 10% 9% 10% 9% 11%
pre-XDR-Cm 77% 42% 18% 16% 13% 11% 15% 15% 10% 8% 10% 14% 13% 9% 10% 3% 12% 13% 13% 6%
pre-XDR-Km-Cm 76% 42% 20% 25% 26% 33% 30% 34% 29% 28% 29% 23% 24% 15% 20% 19% 18% 17% 11% 13%
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